Search Results
Chairman, CDIB Capital Healthcare Ventures Head, CDIB Capital Healthcare Ventures II L.P. Achievements Mr. Ho has almost 30 years of experience in industrial policy, VC investment and executive management.
COMPANY. long-acting release drug products for opioid use disorder, chronic pain, and major depressive disorder. Immunotherapies for cancer with myeloid checkpoint inhibitors. Development of medicine for central nervous system disorders. Small-molecule treatments of non-small cell lung cancer, etc.
With an industry-leading international team, we play a pivotal leading role in Taiwan's venture capital and private equity market. Our Leadership Team. ... President, CDIB Capital Healthcare Ventures. Robert Liu Robert Liu. Managing Director, CDIB YIDA Healthcare Fund. Yen Lu Yen Lu. President, CDIB Yida Private Equity (Kunshan) Co. Ltd.
President, CDIB Capital Healthcare Ventures Managing Director, CDIB Capital Healthcare Ventures II Achievements Ms. Hsu has 25 years of experience in venture capital, and has participated in the establishment of CDIB Capital Healthcare Ventures and CDIB Capital Healthcare Ventures II since 2012. Career Highlights Auditor KPMG Investment Manager
We capitalize on different investment strategies to generate superior risk-adjusted returns. Venture and Growth Capital. Private Equity. Private Credit. NEXT. Venture. We invest in start-up companies with differentiated core strengths, high-growth prospects, asset-light business models, and huge market potential. ACCEPT.
CDIB Capital Healthcare Ventures II led the series B funding round for Acepodia and helped the company successfully raise US$47 million in a very short period of time. Professional Capital Market Experience Even during phases of market volatility, our vast resources and experience in the capital market get our partners results.
Spearheading KKR’s Greater China operations, with AUM over US$ 5 billion in areas of digital economy, healthcare, education, and advanced manufacturing. Under Paul’s leadership, the scope of KKR’s China franchise has expanded beyond private equity investments to commercial real estate, private credit, infrastructure, and technology ventures.
After joining CDF, Mr. Chang helped raise several private equity/ venture capital funds, including RMB CDIB Private Equity (Fujian) Fund, RMB CDIB Yida Private Equity (Kunshan) Fund, and NTD CDIB Capital Healthcare Venture II, and assisted in CDF’s acquisition of KGI Securities in 2012, Cosmos Bank in 2014 and a 25% stake in China Life in 2017.
He joined Kohlberg Kravis Roberts (“KKR”) as a Partner and CEO of Greater China in 2017. Prior to KKR, Paul was President and CEO of CDF and CDIB, as well as the Chairman of CDIB Capital International. Prior to CDF, Paul served as Managing Director at Development Bank of Singapore where he was responsible for DBS Bank’s private equity ...
Seasoned Leader and Ops Expert on Value Creation for Regional Investments. Prior to joining CDIB Capital Internaional, Stephen served as Managing Director of PingAn Capital in Shanghai, responsible for portfolio monitoring, value creation, exit management, and risk assessment. Before that, Stephen was Director of the Asia Operations Team of CVC ...